Amarin Corp Plc (AMRN): New Preston Mason publication RATIONA...

Reply Private New

Replies (2) Next 10 Prev Next

Send PM Follow Ignore

Followers	14
Posts	306
Boards Moderated	0
Alias Born	01/17/2021

lettruthringout

Re: None

Thursday, 02/10/2022 1:20:11 PM

Thursday, February 10, 2022 1:20:11 PM

New Preston Mason publication

RATIONALE FOR DIFFERENT FORMULATIONS OF OMEGA-3 FATTY ACIDS LEADING TO DIFFERENCES IN RESIDUAL CARDIOVASCULAR RISK REDUCTION

Preston Mason
Samuel C.R. Sherratt
Robert H. Eckel

Published:February 10, 2022

Metabolism Journal - Clinical and Experimental

Cardiovascular outcome trials (CVOTs) have used omega-3 fatty acids (n3-FAs) to test if patients with residual risk and well-controlled LDL cholesterol levels benefit from specific lowering of plasma triglycerides (TG). Despite similar reductions in TG levels, the results of these trials have been highly inconsistent. This has led to interest in the role of n3-FA formulation, including the content of eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA), as a basis for different clinical outcomes.

https://www.metabolismjournal.com/article/S0026-0495(22)00039-7/fulltext